Complement and the Alternative Pathway Play an Important Role in LPS/D-GalN-Induced Fulminant Hepatic Failure by Sun, Shihui et al.
Complement and the Alternative Pathway Play an
Important Role in LPS/D-GalN-Induced Fulminant
Hepatic Failure
Shihui Sun
1., Yan Guo
1., Guangyu Zhao
1, Xiaojun Zhou
1, Junfeng Li
1, Jingya Hu
1, Hong Yu
1,Y uC h e n
2,
Hongbin Song
3, Fei Qiao
4, Guilian Xu
5, Fei Yang
5, Yuzhang Wu
5, Stephen Tomlinson
4, Zhongping
Duan
2*, Yusen Zhou
1*
1State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China, 2Beijing You-An Hospital, Artificial Liver Center,
Capital University of Medical Sciences, Beijing, China, 3Institute of Disease Control and Prevention, Academy of Military Medical Science, Beijing, China, 4Department of
Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina, United States of America, 5Institute of Immunology, College of Basic
Medical Sciences, Third Military Medical University, Chongqing, China
Abstract
Fulminant hepatic failure (FHF) is a clinically severe type of liver injury with an extremely high mortality rate. Although the
pathological mechanisms of FHF are not well understood, evidence suggests that the complement system is involved in the
pathogenesis of a variety of liver disorders. In the present study, to investigate the role of complement in FHF, we examined
groups of mice following intraperitoneal injection of LPS/D-GalN: wild-type C57BL/6 mice, wild-type mice treated with a
C3aR antagonist, C5aR monoclonal antibody (C5aRmAb) or CR2-Factor H (CR2-fH, an inhibitor of the alternative pathway),
and C3 deficient mice (C3
2/2 mice). The animals were euthanized and samples analyzed at specific times after LPS/D-GalN
injection. The results show that intraperitoneal administration of LPS/D-GalN activated the complement pathway, as
evidenced by the hepatic deposition of C3 and C5b-9 and elevated serum levels of the complement activation product C3a,
the level of which was associated with the severity of the liver damage. C3a receptor (C3aR) and C5a receptor (C5aR)
expression was also upregulated. Compared with wild-type mice, C3
2/2 mice survived significantly longer and displayed
reduced liver inflammation and attenuated pathological damage following LPS/D-GalN injection. Similar levels of protection
were seen in mice treated with C3aR antagonist,C5aRmAb or CR2-fH. These data indicate an important role for the C3a and
C5a generated by the alternative pathway in LPS/D-GalN-induced FHF. The data further suggest that complement inhibition
may be an effective strategy for the adjunctive treatment of fulminant hepatic failure.
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Introduction
Fulminant hepatic failure (FHF) is a severe clinical syndrome
characterized by hepatic cell injury resulting from a variety of
hepatic disease processes, leading to multiorgan failure [1,2].
Although the incidence of FHF is low, the associated mortality is
extremely high and is always related to liver transplantation, viral
infection and shock [3]. Bacterial lipopolysaccharide (LPS), the
main pathogenic component of gram-negative bacteria, can cause
systemic inflammatory response syndrome, which may lead to
acute liver injury and multiorgan failure. D-galactosamine (D-
GalN) increases the sensitivity of mice to LPS and augments the
lethal effects of LPS [4,5]. Mouse models of LPS/D-GalN-
induced hepatitis have been previously described [6,7]. It has
been reported that tumor necrosis factor (TNF)-a-mediated
hepatocyte apoptosis may be the cause of LPS-induced liver
injury [8–10].
The complement system plays important roles in mediating
both acquired and innate responses against microbial infection
and in immune homeostatic processes, such as the removal of
immune complexes and apoptotic cells [11]. Recent evidence from
several studies has suggested that the complement system is
involved in the pathogenesis of a variety of liver disorders,
including liver fibrosis, viral hepatitis, alcoholic liver disease and
hepatic ischemia/reperfusion injury (IRI) [12–16]. In these disease
settings, complement activation products promote tissue inflam-
mation and injury, particularly via the generation of the
complement activation products C3a and C5a, which promote
inflammation via direct and indirect mechanisms by interacting
with their receptors [17–19].
Although complement activation has been reported in LPS-
treated liver and lung tissues [20–22], little is known about the role
of complement in FHF, especially during the early period of the
disease. In this study, the role of complement in fulminant hepatic
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induced FHF mouse model. Our study further analyzed the
important role of alternative pathway-generated C3a in LPS/D-
GalN-induced FHF and suggested a promising strategy for the
adjunctive clinical treatment of fulminant hepatic failure.
Materials and Methods
Ethics statement
All procedures involving animals were approved by the
Laboratory Animal Center, State Key Laboratory of Pathogen
and Biosecurity, Beijing Institute of Microbiology and Epidemi-
ology IACUC’s (The permitted number is BIME 2009-15). The
study of animals was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals.
Animals and materials
Wild-type (wt) female C57BL/6 and C3
2/2 female mice
(B6.129S4-C3
tm1Crr/J) 8 weeks of age and weighing 20–25 g were
used in this study. Lipopolysaccharide (LPS; from Escherichia coli
strain 0111:B4) and D-GalN were purchased from Sigma. All
drugs were dissolved in pyrogen-free saline. The C3aR antagonist
(SB 290157, #559410) was purchased from Calbiochem.
Monoclonal antibody to mouse C5aR (HM1076) was purchased
from Hycult Biotechnology B.V (Hycult Biotechnology, The
Netherlands). CR2-fH was prepared as previously described [23].
Treatment of mice with LPS/D-GalN
The mice were divided into the following groups: wt mice
treated with LPS/D-GalN (wt group), C3
2/2 mice treated with
LPS/D-GalN (C3
2/2 group), wt mice treated with LPS/D-GalN
and C3aR antagonist (C3aR antagonist group), wt mice treated
with LPS/D-GalN and C5aRmAb (C5aRmAb group), and wt
mice treated with LPS/D-GalN and CR2-fH (CR2-fH group).
Wild-type mice treated with saline were used as the control group
(0 hour group). The treatment protocols were as follows. The
C3aR antagonist (2 mg/kg, diluted in saline containing 0.5%
DMSO) and C5aRmAb (600 ug/kg) was injected i.v. 45 min
before and 45 min after the LPS/D-GalN injection. CR2-fH
(40 mg/kg) dissolved in PBS was injected i.v. immediately after the
LPS/D-GalN injection. The dose of C3aR antagonist and CR2-
fH used was based on previously reported doses and were in line
with doses used in various mouse models of inflammation and
injury [24–26]. LPS/D-GalN was dissolved in 200 ml saline and
injected i.p. at 2.5 mg/kg LPS and 300 mg/kg D-GalN. The
animals were euthanized 0, 1, 4 and 8 hours after the LPS/D-
GalN injection. Plasma or serum samples were collected for the
analysis of C3a, liver enzymes and proinflammatory cytokines.
Liver tissues were processed for histopathological analysis and
immunostaining to evaluate the C3, C3aR, C5aR and C5a-9
deposition and the expression of C3aR mRNA and C5aR mRNA.
Histological analysis of liver damage
The liver tissue was fixed in 10% formalin at room temperature
and subsequently embedded in paraffin. Liver sections from each
animal were sliced and stained with Hematoxylin and eosin
(H&E). The extent of the liver damage was assessed by two
independent observers blinded to the treatment groups.
Measurement of serum C3a levels in mice
To assess whether complement was activated in the liver by
LPS/D-GalN, plasma levels of the complement activation product
C3a were measured using ELISA (BD Pharmingen). Briefly, a 96-
well plate was coated with purified rat anti-mouse C3a antibody
(BD Pharmingen, 558250) overnight at 4uC and then blocked with
10% FBS for 1 hour at room temperature. The samples were
diluted 1:2 in blocking buffer and incubated for 2 hours. Bound
C3a was detected using a biotinylated rat anti-mouse C3a
antibody (BD Pharmingen, 558250) and avidin/horseradish
peroxidase(BD Pharmingen, 554058). Reactive C3a levels were
measured using the TMB substrate solution (BD Pharmingen
555214).
Immunostaining to assess complement deposition
Frozen liver sections were sliced and fixed in cold acetone. The
sections were incubated overnight at 4uC with rat anti-mouse
C3mAb (1:20 dilution, HyCult Biotechnology bv, Uden, Nether-
lands), rabbit anti-mouse C3aR polyclonal antibody(1:50 dilution,
Santa Cruz Biotechnology), rabbit anti-mouse C5aR polyclonal
antibody (1:80 dilution, Santa Cruz Biotechnology) and anti-C5b-
9 polyclonal antibody (5 ug/ml, Calbiochem,SanDiego,CA).
Biotinylated IgG was then added, followed by an avidin-biotin-
peroxidase conjugate (Beijing Zhongshan Biotechnology Co.,
Ltd.). Immunoreactivity was detected using DAB and by
counterstaining with hematoxylin.
Biochemical evaluation of liver injury and
proinflammatory cytokine expression in serum
Blood was collected at 0, 1, 4 and 8 hours. Serum samples were
prepared as previously described [27] and stored at 280uC. The
extent of liver injury was determined by measuring the
concentrations of alanine aminotransferase (ALT) and proinflam-
matory cytokines (IL-6, IL-10, MCP-1, IFN-c, TNF-a, and IL-
12p70) in the serum. ALT was measured using a Beckman CX5
Chemistry Analyzer. The cytokines were assayed using the BD
TM
CBA Mouse Inflammation Kit (Cat.No. 552364) according to the
manufacturer’s instructions.
Detection of C3aR mRNA and C5aR mRNA by relative
quantitative real-time PCR
Total RNA was isolated from the liver tissue using the RNeasy
Mini kit (Qiagen) according to the manufacturer’s instructions.
Any genomic DNA contamination was eliminated by treating the
samples with RNase-free DNase (Promega). RT was performed
with 1 mg of total RNA, using an RT kit (TaKaRa) according to
the manufacturer’s instructions. After the reverse transcription
step, which comprised incubations for 45 min at 48uC, 5 min at
99uC and 5 min at 5uC, C3aR mRNA and C5aR mRNA
expression levels (normalized to GAPDH) were quantified using
SYBR Green real-time PCR (TIANGEN, China) with primers
Figure 1. Complement activation following LPS/D-GalN injection. Wt C57BL/6 mice were injected i.p. with LPS/D-GalN and euthanized at 0,
1, 4 and 8 hours after the injection. (A–L) Immunohistochemical staining for C3, C3aR and C5aR in liver sections after the LPS/D-GalN injection. (M–N)
The relative C3aR mRNA and C5aR mRNA expression levels were determined in live tissue at the indicated time points after the LPS/D-GalN injection.
The mRNA expression was determined by relative quantitative real-time PCR analysis. The results are expressed as the means6SEM relative to GAPDH
expression. (O) The serum concentrations of C3a at the indicated times after the LPS/D-GalN injection. ** and *** indicate p,0.01 and p,0.001,
respectively. n=6–7 per group. The original magnification for C3 of stained images: 6200; for C3aR and C5aR of stained images: 6800.
doi:10.1371/journal.pone.0026838.g001
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59-tctcactgaggcatctattcagtt-39 and antisense 59-attgccgtgctacgttctg-
39. The primers for C5aR were sense 59cgctcatcctgctcaacat-39 and
antisense 59-acggtcggcactaatggtag-39. The relative C3aR and C5aR
expression data were analyzed using the 2
2DDCT method [28].
Survival analysis
In the survival study, an additional eight mice in each group (the wt,
C3
2/2, C3aR antagonist, C5aRmAb and CR2-fH groups) were
monitored for 24 hours period after which all mice were euthanized.
Any mice showing signs of severe distress such as weakness, lack of
mobility, severe jaundice and presented moribund conditions during
this period were euthanized and recorded as end point in survival
study. Mice in the event of severe distress were euthanized by overdose
of pentobarbital (150 mg/kg, i.p.) followed by cervical dislocation.
Statistical analysis
The significance of differences between groups was analyzed using
a one-way ANOVA and subjected to Tukey’s multiple comparisons
test. Differences in cytokine and ALT levels between the groups at the
indicated times were analyzed using a two-way ANOVA. Survival
differences were analyzed using a Kaplan-Meier survival curve with a
log-rank test. The data are represented as the mean6SEM. All the
analyses were performed using GraphPad Prism software. P values
lower than 0.05 were considered statistically significant.
Results
Complement activation in fulminant hepatic failure
induced by LPS/D-GalN
C3 was deposited in the liver parenchyma of the LPS/D-GalN-
treated mice, as detected by immunohistochemistry. A low level of
C3 deposition was detected around the central vein (CV) at the 0-
hour time point (Fig. 1A), whereas increased levels of C3
deposition were observed in the parenchyma, especially around
the CV, 1 hour after the LPS/D-GalN injection (Fig. 1B),
although no obvious pathologic injury was detected. The C3
deposition levels in the liver sections progressively increased over
time after the LPS/D-GalN injection, reaching their highest value
at 8 hours, primarily in the centrilobular regions (Fig. 1C and D).
Protein and gene expression levels of C3aR and C5aR were
analyzed in liver tissue samples isolated at 0, 1, 4 and 8 hours post-
LPS/D-GalN injection by immunohistochemistry and relative
quantitative real-time RT-PCR. The results show that C3aR and
C5aR expressed on non-parenchymal cells, especially kupffer cells
in mice without LPS/D-GalN injection. However, the expression of
C3aR and C5aR on both non-parenchymal cells and hepatocytes
increased with time after LPS/D-GalN injection (Fig. 1E–L). C3aR
mRNA and C5aR mRNA expression levels correlated with
immunohistological data. C3aR mRNA increased 1 hour after the
LPS/D-GalN injection, but we consistently found that C3aR
mRNA levels returned to near control levels at 4 hours, and then
increased again at 8 hours after the LPS/D-GalN injection
(p,0.01) (Fig. 1M). In contrast, the C5aR expression linearly
increased with time throughout the 8 hour period following the
LPS/D-GalN injection (Fig. 1N). In addition, the plasma C3a levels
were significantly elevated as early as 1 hour after the LPS/D-GalN
injection and remained elevated for 8 hours (Fig. 1O). Collectively,
the above data demonstrate significant complement activation in
the liver post-LPS/D-GalNinjection, and the extent of complement
activation correlated with the severity of the liver injury.
C3 deficiency attenuates LPS/D-GalN-induced pathologic
damage in the liver
C3 activation is the central step in the complement cascade;
therefore, we investigated the effects of C3 deficiency on LPS/D-
Figure 2. C3 deficiency alleviated liver injury after the LPS/D-
GalN injection. Wt C57BL/6 mice and C3
2/2 mice were injected with
LPS/D-GalN i.p. and euthanized at 0, 1, 4 and 8 hours after the LPS/D-
GalN injection. Theleft panels(A–D)shows the H&E staining of wt C57BL/
6 mouse liver sections at the designated time points and demonstrates
the progression of liver damage over time. The right panels (G–J) shows
the corresponding liver sections of the C3
2/2 mice, revealing less severe
liver damage. (E, K) Immunohistochemical staining for C5b-9 in liver
sections in wt mice and C3
2/2 mice 8 hours after LPS/D-GalN injection.
(F, L) Depiction of whole explanted livers demonstrating the different
degree of hemorrhage. Each image is representative of 4–5 mice per
group. Magnification of the H&E stained images: 6200.
doi:10.1371/journal.pone.0026838.g002
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2/2 mice
displayed a significantly lower degree of liver injury after the LPS/
D-GalN treatment compared with the wt mice. A detailed
examination of whole livers and the H&E staining of mouse liver
sections 8 hours after the LPS/D-GalN injection indicated a much
lower degree of hemorrhage with less severe vascular congestion,
hepatocellular damage and inflammatory cell infiltration in the
C3
2/2 mice (Fig. 2G–J and L) compared to the wt mice (Fig. 2A–
D and F). The deposition of C5b-9 was detected in wt mice but no
C5b-9 deposition in C3
2/2 mice (Fig. 2E and K). The serum ALT
concentrations were also significantly lower in the C3
2/2 mice
compared with the wt mice from 4 to 8 hours after the LPS/D-
GalN injection (Fig. 3A). The serum levels of TNF-a and IL-6
were significantly lower in the C3
2/2 mice than in the wt mice at
1 hour after the LPS/D-GalN injection, returning to baseline in
both groups by 4 hours (Fig. 3B and C). There was no significant
Figure 3. The effects of C3 deficiency on inflammation and survival after LPS/D-GalN injection. (A) The response patterns to different
ALT concentrations in C3
2/2 and wt mice (n=4–5). (B–D) The serum levels of proinflammatory cytokines after LPS/D-GalN injection. The
concentrations of TNF-a and IL-6 in the C3
2/2 mice were lower than in the wt C57BL/6 mice at 1 hour, but the levels of these cytokines in both
groups decreased to the same concentrations at later time points. There was no difference in MCP-1 between the groups (n=4–5). (E) The C3
2/2
mice had prolonged life spans and an increased survival rate after LPS/D-GalN injection (n=8). *** indicate p,0.001, in the comparison between the
C3
2/2 and C57BL/6 groups. The means6SEM are shown. The results are representative of 3 separate experiments.
doi:10.1371/journal.pone.0026838.g003
Complement and Fulminant Hepatic Failure
PLoS ONE | www.plosone.org 5 November 2011 | Volume 6 | Issue 11 | e26838Complement and Fulminant Hepatic Failure
PLoS ONE | www.plosone.org 6 November 2011 | Volume 6 | Issue 11 | e26838difference in the MCP-1 levels between the C3
2/2 and wt mice
after the LPS/D-GalN injection (Fig. 3D). We also found no
differences in the serum levels of IL-10, IFN-c or IL-12p70 between
the C3
2/2 and wt mice after the LPS/D-GalN injection (data not
shown). Notably, C32/2 mice demonstrated a significantly
improved survival rate after LPS/D-GalN injection compared with
the wt mice, with approximately 30% of the C3
2/2 mice surviving
for 24 hours compared with a 100% mortality rate for wt mice by
12 hours after the LPS/D-GalN challenge (P,0.001, n=8)
(Fig. 3E). All mice surviving for 24 hours recovered from any signs
of morbidity and appeared healthy. Taken together, these data
indicate that C3
2/2 deficiency provides protection against liver
injury induced by LPS/D-GalN.
Inhibition of C3aR signaling suppresses liver
inflammation and attenuates the LPS-D/GalN-induced
liver damage
As shown in Fig. 1, the mRNA expression of both C3aR and
C5aR was upregulated following the LPS/D-GalN-induced liver
injury. The complement activation products C3a and C5a are
known candidates for mediating liver damage. Therefore, we
investigated the effects of C3aR inhibition on liver inflammation
and injury. A gross examination of livers and a microscopic
analysis of liver sections from mice 8 hours after the LPS/D-GalN
injection revealed that the treatment with the C3aR antagonist
markedly reduced the amount of liver hemorrhage and paren-
chymal damage compared with the saline group mice after the
LPS/D-GalN injection (Fig. 4A, B, D and E). This reduced injury
was associated with less C3 deposition in the liver tissues of the
C3aR antagonist-treated mice compared with the control group
(Fig. 4C and F). Blocking the interaction of C3a with C3aR also
reduced the C3aR mRNA and C5aR mRNA levels compared with
the saline group and resulted in a more significant reduction in the
C5aR mRNA compared with that of C3aR mRNA (Fig. 4G and
H). Furthermore, the ALT levels were also significantly lower in
the C3aR antagonist-treated mice compared with the saline group
from 4 to 8 hours post-LPS/D-GalN injection (Fig. 4I). The serum
levels of TNF-a, IL-6 and MCP-1 were reduced in the C3aR
antagonist-treated mice at the early time points after LPS/D-GalN
injection; however, 4 hours later, the MCP-1 level had increased
in the C3aR antagonist-treated mice (Fig. 4J–L). Finally, C3aR
blockage improved the survival rate of the LPS/D-GalN-injected
mice (P,0.01, n=8) (Fig. 4M).
Inhibition of C5aR signaling and targeted complement
inhibition alleviates liver injury in LPS/D-GalN-injected
mice
The effects of C5aR inhibition on liver inflammation and injury
were also studied. The results were similar to that of C3aR
antagonist treatment with attenuated liver hemorrhage and
parenchymal damage, decreased C3 deposition compared with
the control mice (Fig. 5A–F), and improved the survival rate
(P,0.01, n=8) (Fig. 5J). These results indicated an important role
for C5a in mediating LPS/D-GalN-induced liver injury in mice.
Furthermore, the role of the alternative complement pathway
was investigated in our injury model using CR2-fH, a complement
inhibitor that targets the sites of complement activation and
specifically inhibits the alternative pathway [26]. Mice were
treated with 0.8 mg CR2-fH i.v. immediately after LPS/D-GalN
administration, with saline used as the control treatment. After
8 hours, the CR2-fH-treated mice displayed minimal evidence of
focal hemorrhage and parenchymal damage compared with the
control group (Fig. 5G and H). C3 deposition was also significantly
reduced in the CR2-fH-treated mice compared with the control
group (Fig. 5I). Almost 50% of the CR2-fH-treated mice survived
for 24 hours, whereas all the control group mice died by 12 hours
post-LPS/D-GalN injection (p,0.001, n=8) (Fig. 5K). These data
indicate a key role for the alternative complement pathway in
causing liver injury in this model.
Discussion
Acute liver injury is a dramatic clinical syndrome with a high
mortality rate and is characterized by sudden and severe damage
to hepatic cells, leading to multiorgan failure [29,30]. Inflamma-
tory cytokines, especially TNF-a, have been linked to the
pathogenesis of hepatocyte apoptosis and liver injury [8–10].
Recent evidence has indicated a role for complement in the
pathogenesis of a variety of liver diseases [13,31,32]. Immunohis-
tochemistry analyses performed in patients with fulminant and
acute hepatitis have shown that the membrane attack complex
(MAC) is deposited around necrotic areas, indicating activation of
the complement system and its involvement in the pathogenesis of
liver injury [13]. In a hemorrhagic shock and tissue trauma (HS/
T) mouse model, complement factor 3 deficiency or temporary C3
depletion by CVF led to both reduced transaminase levels and a
blunted cytokine release, with a well-preserved hepatic structure
[31]. In a previous study by Stephen Tomlinson [16] in an IRI
mouse model, complement was found to play a key role in the
enhanced susceptibility of steatotic livers to IRI. The results of
these studies led us to hypothesize that the activation of
complement or its activation products may mediate hepatic injury
in FHF.
LPS is the main pathogenic factor of gram-negative bacteria
and can cause systemic inflammatory response syndrome, which
may lead to FHF and multiorgan failure. LPS/D-GalN-treated
mouse models are frequently used to study the pathogenesis of
liver injury [8,9,10]. In this study, the data from the mouse model
with FHF induced by LPS/D-GalN demonstrated that liver injury
was associated with elevated serum C3a levels, extensive hepatic
deposition of C3 and increased hepatic expression of C3aR mRNA
and C5aR mRNA, along with elevated serum levels of proin-
flammatory cytokines and ALT. However, all of the measured
parameters of inflammation and injury were significantly reduced
by C3 deficiency, blockage of C3aR or inhibition of the alternative
complement activation pathway. These data suggest an important
role for complement activation, especially the alternative comple-
ment activation pathway, in the pathogenesis of LPS/D-GalN-
induced liver injury.
Figure 4. Alleviation of the liver injuries in mice after treatment with C3aR antagonist. (A–F) C3aR antagonist group mice displayed
reduced liver damage (A–B, D–E) and decreased C3 deposition (C, F) 8 hours after LPS/D-GalN injection. (G–H) C3aR mRNA expression decreased at
8 hours compared with that of the saline group, whereas C5aR mRNA expression decreased from 4 to 8 hours (n=4–5). (I) The different response
patterns of ALT concentration in the C3aR antagonist group mice and the wt mice (n=4–5). (J–L) The concentrations of TNF-a and IL-6 in the C3aR
antagonist mice were lower than in the saline group. There was a delayed increase in MCP-1 in the C3aR antagonist group (n=4–5). (M) Treatment
with the C3aR antagonist increased the survival rate of the mice after LPS/D-GalN injection (n=8). *, **and *** indicate p,0.05, p,0.01 and p,0.001,
respectively, relative to the saline group. The means6SEM are shown. Magnification of the H&E and immunohistochemically stained images: 6200.
The results are representative of 3 separate experiments.
doi:10.1371/journal.pone.0026838.g004
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PLoS ONE | www.plosone.org 7 November 2011 | Volume 6 | Issue 11 | e26838Figure 5. Inhibition of C5aR signaling and targeted complement inhibition alleviates liver injury. (A–I) Both C5aRmAb and CR2-fH
groups displayed reduced liver damage (A–B, D–E, G–H) and decreased C3 deposition (C, F, I) 8 hours after LPS/D-GalN injection. (J) The different
response patterns of ALT concentration in the C3aR antagonist mice and the wt mice (n=4–5). (J–K) Treatment with the C5aR antagonist or CR2-fH
increased the survival rate of the mice after LPS/D-GalN injection (n=8). ** and *** indicate p,0.01 and p,0.001, respectively, relative to the saline
group. The means6SEM are shown. Magnification of the H&E and immunohistochemically stained images:6200. The results are representative of 3
separate experiments.
doi:10.1371/journal.pone.0026838.g005
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PLoS ONE | www.plosone.org 8 November 2011 | Volume 6 | Issue 11 | e26838The anaphylatoxins C3a and C5a are proinflammatory
polypeptides generated by the activation of the complement
cascade. Both C3a and C5a have multifunctional roles in liver
inflammation and regeneration via interactions with their cognate
receptors, C3aR and C5aR, respectively. C5aR has been shown to
be constitutively expressed in Kupffer cells and stellate cells under
normal conditions, but its expression is increased in hepatocytes in
response to inflammatory cytokines [33,34,35,36]. To identify the
potential roles of complement activation products in the
production of inflammatory cytokines in mice challenged with
LPS/D-GalN, we investigated the effect of C3aR or C5aR
blockage respectively on LPS/D-GalN-induced liver inflamma-
tion. Blocking the binding of C3a and C5a to their receptors
protected mice against liver injury apparently. Furthermore, C3aR
antagonist reduced the levels of the inflammatory cytokines TNF-a
and IL-6, which suggests that the induction of inflammatory
cytokines in our model was dependent on complement. These data
are in agreement with previous in vitro findings [37,38] that C3a
and C5a enhanced the release of IL-6 and TNF-a in a dose-
dependent and PGE2-independent manner and that C5aR
antagonist treatment after partial hepatic ischemia and reperfusion
significantly decreased serum and tissue TNF-a level and
attenuated liver histopathology [39].
Although C3a is generally a less potent mediator than C5a, the
serum concentration of C3 is 10 times higher than that of C5 [40].
C3a also regulates vasodilation, increases the permeability of small
blood vessels, and induces contraction of smooth muscles. Besides,
C3a triggers oxidative burst in macrophages, neutrophils and
eosinophils [41,42,43], and regulates the synthesis of IL-6 and
TNF-a from B cells and monocytes [37]. Studies have found that
blockade or knockout of C3aR effectively attenuated tissue
damage [44,45,46,47] and C3aR
2/2 mice are more susceptible
than wt mice to an i.v. challenge with LPS [48]. In a rat model of
ARDS, C3a had profound systemic hemodynamic and systemic
cytokine effects, whereas, C5a exerted direct intra-lung modula-
tion of neutrophil infiltration and cytokine production [49]. In our
previous study on acute lung injury induced by paraquat in a
mouse model, C3aR inhibition significantly attenuated lung injury
and increased the survival rate after paraquat administration [25].
Collectively, the blockade of C3a receptor in this study is capable
of offering a significant survival benefit by decreasing the
inflammatory response. Also, we found that the blockade of both
C3a and C5a signals had similar level of protection (data not
shown).
Along with the inflammatory function of complement activa-
tion, its potential role in liver regeneration has been recently
investigated [50,51]. He S et al. [52] found that in a combined
model of IRI and PHx, both C3 deficiency and high-dose CR2-
Crry, an inhibitor of C3 activation, produced severe hepatic injury
and high mortality, whereas low-dose CR2-Crry was protective
and strengthened hepatic proliferative responses. Taken together,
these data confirm the multiple roles of complement activation in
liver diseases and indicate that complement activation may have
an important role in the pathogenesis of liver injury in our mouse
model of FHF induced by LPS-D/GalN.
In our model, increased C3aR mRNA expression displayed a
two-wave pattern, whereas C5aR mRNA expression increased
progressively following LPS/D-GalN injection, suggesting that
C3a/C3aR and C5a/C5aR signaling may have different functions
at different stages of liver injury progression. The first phase of
complement activation may be related to the priming of liver cells
shortly after LPS-D/GalN injection [36]. Our results show that,
compared with the C3aR expression trend, the C3aR antagonist
significantly downregulated C5aR expression following LPS/D-
GalN injection, which indicates that C5a may also contribute to
LPS-induced liver injury. C5a has generally been regarded as a
more potent proinflammatory mediator than C3a. Previous studies
have shown that C5a stimulated the synthesis of proinflammatory
cytokines and enhanced the transcription of type II acute phase
protein a2-macroglobulin in the liver [34,53]. Therefore, our data
showing a sharply decreased expression of C5aR further indicate
the crucial function of C5a in mediating liver damage in LPS-D/
GalN-induced FHF.
In summary, we demonstrated an essential role for complement
activation, especially the alternative activation pathway, in the
pathogenesis of LPS/D-GalN-induced liver injury. The interac-
tion of anaphylatoxins with their receptors plays a role in the
hepatic damage in this model. Inhibiting complement activation
represents a potential therapeutic approach for the adjunctive
treatment of LPS-induced fulminant hepatic failure.
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